AKR1B1 and neuropathy: For example, the Michigan Neuropathy Screening Instrument (MNSI), used in the study of the aldose reductase inhibitor zenarestat, terminated for reasons of toxicity [2], represents the screening component of a two-step test requiring ultimate confirmation of neuropathy by measurement with the Michigan Diabetic Neuropathy Score (MDNS) [3].